Endometrial carcinoma, a cancer of the lining of the uterus, is the most common gynecologic malignancy in developed nations. Over the past decade, its incidence has steadily increased (approximately 1 ...

The U.S. Food and Drug Administration has approved Merck's Keytruda (pembrolizumab) plus chemotherapy as treatment for adult patients with primary advanced or recurrent endometrial carcinoma. This is ...

Endometrial cancer ranks as the most common malignancy in gynecology and the sixth most common cancer among women worldwide.

Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY ...

A phase 3 trial demonstrated progression-free survival improvements with Tecentriq-chemotherapy combination in patients with endometrial carcinoma. The treatment combination of Tecentriq (atezolizumab ...

A new review article published in Genes & Diseases sheds light on the complex molecular mechanisms through which tumor-infiltrating immune cells regulate endometrial carcinoma (EC). As one of the most ...

Please provide your email address to receive an email when new articles are posted on . FDA drug approvals have led to significant advancement in endometrial cancer treatment. Stage and histology ...

This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.

The conversation often begins with subtle changes that women might initially dismiss as normal variations in their monthly cycle. Perhaps unusual bleeding between periods, or discharge that seems ...

"Endometrial hyperplasia and cancer are highly affected by obesity and lifestyle factors. Focusing on these factors in diverse communities will lead to our better understanding of these disparities.